Spyre Therapeutics, Inc.
SYRE
$14.67
$0.543.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.44% | -77.74% | 11.45% | 30.58% | -57.53% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.63% | 409.24% | -51.49% | -65.18% | 152.63% |
| Change in Net Operating Assets | 4.32% | 135.50% | -939.50% | 286.42% | 76.57% |
| Cash from Operations | -26.44% | 52.74% | -118.09% | 8.04% | 10.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -499.03% | 135.46% | -14.82% | -197.58% | 63.87% |
| Cash from Investing | -499.03% | 135.46% | -14.82% | -197.58% | 63.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,627.56% | 2,542.02% | -88.72% | -94.83% | 80,697.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 100.11% | -- |
| Repurchase of Preferred Stock | -- | -62.96% | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -321.79% | -- | 100.00% | 75.29% | -- |
| Cash from Financing | 1,665.27% | 3,450.00% | -99.79% | 5.23% | 1,405.61% |
| Foreign Exchange rate Adjustments | -193.75% | -- | 100.00% | -122.22% | 205.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.68% | 114.32% | -571.87% | -60.28% | 167.22% |